Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	minus-end-directed microtubule motor activity	DNAH10 DNAH5 DNAH9 DNAH14	4.84e-07	18	73	4	GO:0008569
GeneOntologyMolecularFunction	arachidonate epoxygenase activity	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.65e-06	24	73	4	GO:0008392
GeneOntologyMolecularFunction	arachidonate monooxygenase activity	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.71e-06	27	73	4	GO:0008391
GeneOntologyMolecularFunction	dynein light intermediate chain binding	DNAH10 DNAH5 DNAH9 DNAH14	3.15e-06	28	73	4	GO:0051959
GeneOntologyMolecularFunction	aromatase activity	CYP2A13 CYP4F8 CYP2C9 CYP2C18	7.90e-06	35	73	4	GO:0070330
GeneOntologyMolecularFunction	dynein intermediate chain binding	DNAH10 DNAH5 DNAH9 DNAH14	9.91e-06	37	73	4	GO:0045505
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	CYP2A13 CYP4F8 CYP2C9 CYP2C18	3.08e-05	49	73	4	GO:0016712
GeneOntologyMolecularFunction	iron ion binding	CYP2A13 CYP4F8 CYP2C9 CYP2C18 PPEF1 PLOD1	3.24e-05	166	73	6	GO:0005506
GeneOntologyMolecularFunction	alpha2-adrenergic receptor activity	ADRA2A ADRA2C	3.95e-05	3	73	2	GO:0004938
GeneOntologyMolecularFunction	monooxygenase activity	CYP2A13 CYP4F8 CYP2C9 CYP2C18 PCBD1	6.38e-05	115	73	5	GO:0004497
GeneOntologyMolecularFunction	cytoskeletal motor activity	DNAH10 MYO3B DNAH5 DNAH9 DNAH14	7.21e-05	118	73	5	GO:0003774
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	CYP2A13 CYP4F8 CYP2C9 CYP2C18 PCBD1 PLOD1	7.72e-05	194	73	6	GO:0016705
GeneOntologyMolecularFunction	linoleic acid epoxygenase activity	CYP2C9 CYP2C18	7.87e-05	4	73	2	GO:0071614
GeneOntologyMolecularFunction	microtubule motor activity	DNAH10 DNAH5 DNAH9 DNAH14	1.26e-04	70	73	4	GO:0003777
GeneOntologyMolecularFunction	epinephrine binding	ADRA2A ADRA2C	1.96e-04	6	73	2	GO:0051379
GeneOntologyMolecularFunction	alpha-adrenergic receptor activity	ADRA2A ADRA2C	1.96e-04	6	73	2	GO:0004936
GeneOntologyMolecularFunction	ATP-dependent activity	NLRP10 ABCA4 DNAH10 DHX37 MYO3B DNAH5 DNAH9 DNAH14 ATP6V0A2	3.90e-04	614	73	9	GO:0140657
GeneOntologyMolecularFunction	adrenergic receptor activity	ADRA2A ADRA2C	5.82e-04	10	73	2	GO:0004935
GeneOntologyMolecularFunction	U3 snoRNA binding	UTP25 DHX37	7.10e-04	11	73	2	GO:0034511
GeneOntologyMolecularFunction	catecholamine binding	ADRA2A ADRA2C	1.00e-03	13	73	2	GO:1901338
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP2C9 CYP2C18	1.17e-03	14	73	2	GO:0008401
GeneOntologyMolecularFunction	transition metal ion binding	LARGE2 AARS1 CYP2A13 CYP4F8 CYP2C9 CYP2C18 SF3A3 PHF14 ZFHX3 SAMHD1 PPEF1 PLOD1	1.18e-03	1189	73	12	GO:0046914
GeneOntologyMolecularFunction	heme binding	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.45e-03	154	73	4	GO:0020037
GeneOntologyMolecularFunction	tetrapyrrole binding	CYP2A13 CYP4F8 CYP2C9 CYP2C18	3.07e-03	164	73	4	GO:0046906
GeneOntologyMolecularFunction	adrenergic receptor binding	ADRA2A ADRA2C	3.45e-03	24	73	2	GO:0031690
GeneOntologyBiologicalProcess	negative regulation of uterine smooth muscle contraction	ADRA2A ADRA2C	1.27e-05	2	74	2	GO:0070473
GeneOntologyBiologicalProcess	olefinic compound metabolic process	CYP2A13 CYP4F8 CYP2C9 ABCA4 CYP2C18 PRKG1	4.60e-05	180	74	6	GO:0120254
GeneOntologyBiologicalProcess	negative regulation of smooth muscle contraction	ADRA2A ADRA2C PRKG1	6.50e-05	22	74	3	GO:0045986
GeneOntologyBiologicalProcess	epoxygenase P450 pathway	CYP2A13 CYP2C9 CYP2C18	6.50e-05	22	74	3	GO:0019373
GeneOntologyBiologicalProcess	receptor transactivation	ADRA2A ADRA2C	7.58e-05	4	74	2	GO:0035624
GeneOntologyBiologicalProcess	organic hydroxy compound metabolic process	CYP4F8 CYP2C9 CYP2C18 SYNJ1 PRKG1 CTNS IDH3B CHKA PCBD1 IP6K2	9.38e-05	641	74	10	GO:1901615
GeneOntologyBiologicalProcess	adenylate cyclase-activating adrenergic receptor signaling pathway	ADRA2A ADRA2C AKAP13	9.63e-05	25	74	3	GO:0071880
GeneOntologyBiologicalProcess	arachidonate metabolic process	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.04e-04	68	74	4	GO:0019369
GeneOntologyBiologicalProcess	cilium movement involved in cell motility	DNAH10 CFAP61 DNAH5 DNAH9 ADCY3 DNAH14	1.08e-04	210	74	6	GO:0060294
GeneOntologyBiologicalProcess	alcohol metabolic process	CYP2C9 CYP2C18 SYNJ1 PRKG1 IDH3B CHKA PCBD1 IP6K2	1.13e-04	412	74	8	GO:0006066
GeneOntologyBiologicalProcess	cilium-dependent cell motility	DNAH10 CFAP61 DNAH5 DNAH9 ADCY3 DNAH14	1.23e-04	215	74	6	GO:0060285
GeneOntologyBiologicalProcess	cilium or flagellum-dependent cell motility	DNAH10 CFAP61 DNAH5 DNAH9 ADCY3 DNAH14	1.23e-04	215	74	6	GO:0001539
GeneOntologyBiologicalProcess	negative regulation of muscle contraction	ADRA2A ADRA2C PRKG1	2.67e-04	35	74	3	GO:0045932
GeneOntologyBiologicalProcess	adrenergic receptor signaling pathway	ADRA2A ADRA2C AKAP13	2.67e-04	35	74	3	GO:0071875
GeneOntologyBiologicalProcess	cilium movement	DNAH10 CFAP61 DNAH5 DNAH9 ADCY3 DNAH14	3.50e-04	261	74	6	GO:0003341
GeneOntologyCellularComponent	dynein complex	DNAH10 DNAH5 DNAH9 DNAH14	4.00e-05	54	74	4	GO:0030286
GeneOntologyCellularComponent	axonemal dynein complex	DNAH10 DNAH5 DNAH9	9.26e-05	25	74	3	GO:0005858
GeneOntologyCellularComponent	9+2 motile cilium	CUL3 DNAH10 CFAP61 DNAH5 DNAH9 DNAH14	1.99e-04	238	74	6	GO:0097729
GeneOntologyCellularComponent	outer dynein arm	DNAH5 DNAH9	7.97e-04	12	74	2	GO:0036157
GeneOntologyCellularComponent	cuticular plate	CIB2 SPTA1	9.40e-04	13	74	2	GO:0032437
Domain	Dynein_heavy_chain_D4_dom	DNAH10 DNAH5 DNAH9 DNAH14	2.21e-07	14	74	4	IPR024317
Domain	Dynein_HC_stalk	DNAH10 DNAH5 DNAH9 DNAH14	2.21e-07	14	74	4	IPR024743
Domain	MT	DNAH10 DNAH5 DNAH9 DNAH14	2.21e-07	14	74	4	PF12777
Domain	AAA_8	DNAH10 DNAH5 DNAH9 DNAH14	2.21e-07	14	74	4	PF12780
Domain	DHC_fam	DNAH10 DNAH5 DNAH9 DNAH14	3.00e-07	15	74	4	IPR026983
Domain	Dynein_heavy_dom	DNAH10 DNAH5 DNAH9 DNAH14	3.00e-07	15	74	4	IPR004273
Domain	Dynein_heavy	DNAH10 DNAH5 DNAH9 DNAH14	3.00e-07	15	74	4	PF03028
Domain	DHC_N1	DNAH10 DNAH5 DNAH9	3.30e-06	8	74	3	PF08385
Domain	Dynein_heavy_dom-1	DNAH10 DNAH5 DNAH9	3.30e-06	8	74	3	IPR013594
Domain	Dynein_heavy_dom-2	DNAH10 DNAH5 DNAH9	2.11e-05	14	74	3	IPR013602
Domain	DHC_N2	DNAH10 DNAH5 DNAH9	2.11e-05	14	74	3	PF08393
Domain	ATPase_dyneun-rel_AAA	DNAH10 DNAH5 DNAH9	2.11e-05	14	74	3	IPR011704
Domain	AAA_5	DNAH10 DNAH5 DNAH9	2.11e-05	14	74	3	PF07728
Domain	Cyt_P450_E_grp-I	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.99e-05	45	74	4	IPR002401
Domain	Cyt_P450_CS	CYP2A13 CYP4F8 CYP2C9 CYP2C18	5.74e-05	53	74	4	IPR017972
Domain	CYTOCHROME_P450	CYP2A13 CYP4F8 CYP2C9 CYP2C18	7.65e-05	57	74	4	PS00086
Domain	-	CYP2A13 CYP4F8 CYP2C9 CYP2C18	8.19e-05	58	74	4	1.10.630.10
Domain	p450	CYP2A13 CYP4F8 CYP2C9 CYP2C18	8.19e-05	58	74	4	PF00067
Domain	Cyt_P450	CYP2A13 CYP4F8 CYP2C9 CYP2C18	9.36e-05	60	74	4	IPR001128
Domain	HnRNP_R/Q_splicing_fac	A1CF RBM46	1.54e-04	5	74	2	IPR006535
Domain	P-loop_NTPase	SAMD9L NLRP10 ABCA4 UTP25 DNAH10 DHX37 MYO3B HS3ST2 DNAH5 DNAH9 DNAH14	4.83e-04	848	74	11	IPR027417
Domain	ADR_fam	ADRA2A ADRA2C	6.83e-04	10	74	2	IPR002233
Domain	-	SAMD9L NLRP10 ABCA4 UTP25 DNAH10 DHX37 HS3ST2 DNAH5 DNAH9 DNAH14	6.93e-04	746	74	10	3.40.50.300
Domain	AAA+_ATPase	ABCA4 DNAH10 DNAH5 DNAH9	2.57e-03	144	74	4	IPR003593
Domain	AAA	ABCA4 DNAH10 DNAH5 DNAH9	2.57e-03	144	74	4	SM00382
Domain	ANTENNAPEDIA	HOXD1 HOXA1	4.04e-03	24	74	2	PS00032
Pathway	WP_EICOSANOID_METABOLISM_VIA_CYTOCHROME_P450_MONOOXYGENASES	CYP4F8 CYP2C9 CYP2C18	2.45e-05	14	59	3	MM15842
Pathway	WP_MAJOR_RECEPTORS_TARGETED_BY_EPINEPHRINE_AND_NOREPINEPHRINE	ADRA2A ADRA2C ADCY3	3.75e-05	16	59	3	M39849
Pathway	REACTOME_XENOBIOTICS	CYP2A13 CYP2C9 CYP2C18	1.16e-04	23	59	3	M5372
Pathway	WP_OXIDATION_BY_CYTOCHROME_P450	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.29e-04	62	59	4	M39653
Pathway	REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.46e-04	64	59	4	M5650
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SOD1_TO_RETROGRADE_AXONAL_TRANSPORT	DNAH10 DNAH5 DNAH9	1.90e-04	27	59	3	M47755
Pathway	REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS	ADRA2A ADRA2C ADCY3	3.47e-04	33	59	3	MM15058
Pathway	REACTOME_ADRENOCEPTORS	ADRA2A ADRA2C	6.08e-04	9	59	2	M27302
Pathway	REACTOME_ADRENOCEPTORS	ADRA2A ADRA2C	6.08e-04	9	59	2	MM15009
Pathway	KEGG_MEDICUS_REFERENCE_RETROGRADE_AXONAL_TRANSPORT	DNAH10 DNAH5 DNAH9	7.63e-04	43	59	3	M47669
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_RETROGRADE_AXONAL_TRANSPORT	DNAH10 DNAH5 DNAH9	8.72e-04	45	59	3	M47670
Pathway	REACTOME_CYP2E1_REACTIONS	CYP2A13 CYP2C9	9.24e-04	11	59	2	M27130
Pathway	REACTOME_PHASE_I_FUNCTIONALIZATION_OF_COMPOUNDS	CYP2A13 CYP4F8 CYP2C9 CYP2C18	9.32e-04	104	59	4	M738
Pathway	WP_METAPATHWAY_BIOTRANSFORMATION_PHASE_I_AND_II	CYP2A13 CYP4F8 CYP2C9 CYP2C18 HS3ST2	9.91e-04	183	59	5	M39588
Pathway	REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS	ADRA2A ADRA2C ADCY3	1.05e-03	48	59	3	M10775
Pubmed	Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population.	CYP2A13 CYP2C9 CYP2C18	3.45e-06	14	75	3	19290787
Pubmed	Deletion of the α2A/α2C-adrenoceptors accelerates cutaneous wound healing in mice.	ADRA2A ADRA2C	4.59e-06	2	75	2	25186490
Pubmed	Do allelic variants in alpha2A and alpha2C adrenergic receptors predispose to hypertension in blacks?	ADRA2A ADRA2C	4.59e-06	2	75	2	16636200
Pubmed	Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines.	CYP2C9 CYP2C18	4.59e-06	2	75	2	22918969
Pubmed	Alpha2-adrenergic receptor activation regulates cortical interneuron migration.	ADRA2A ADRA2C	4.59e-06	2	75	2	22805283
Pubmed	Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.	CYP2C9 CYP2C18	4.59e-06	2	75	2	8333835
Pubmed	Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure.	ADRA2A ADRA2C	4.59e-06	2	75	2	18632114
Pubmed	Cloning of two mouse genes encoding alpha 2-adrenergic receptor subtypes and identification of a single amino acid in the mouse alpha 2-C10 homolog responsible for an interspecies variation in antagonist binding.	ADRA2A ADRA2C	4.59e-06	2	75	2	1353249
Pubmed	Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice.	ADRA2A ADRA2C	4.59e-06	2	75	2	12384461
Pubmed	Double disruption of α2A- and α2C-adrenoceptors induces endothelial dysfunction in mouse small arteries: role of nitric oxide synthase uncoupling.	ADRA2A ADRA2C	4.59e-06	2	75	2	25037566
Pubmed	Identification of an additional gene belonging to the alpha 2 adrenergic receptor family in the human genome by PCR.	ADRA2A ADRA2C	4.59e-06	2	75	2	1849485
Pubmed	Exercise training delays cardiac dysfunction and prevents calcium handling abnormalities in sympathetic hyperactivity-induced heart failure mice.	ADRA2A ADRA2C	4.59e-06	2	75	2	17975126
Pubmed	Prognostic significance of α- and β2-adrenoceptor gene expression in breast cancer patients.	ADRA2A ADRA2C	4.59e-06	2	75	2	31218733
Pubmed	Chronic Sympathetic Hyperactivity Triggers Electrophysiological Remodeling and Disrupts Excitation-Contraction Coupling in Heart.	ADRA2A ADRA2C	4.59e-06	2	75	2	32409748
Pubmed	Aerobic exercise training improves skeletal muscle function and Ca2+ handling-related protein expression in sympathetic hyperactivity-induced heart failure.	ADRA2A ADRA2C	4.59e-06	2	75	2	20595538
Pubmed	Exercise training improves the net balance of cardiac Ca2+ handling protein expression in heart failure.	ADRA2A ADRA2C	4.59e-06	2	75	2	17244791
Pubmed	Differential involvement of central and peripheral α2 adrenoreceptors in the antinociception induced by aerobic and resistance exercise.	ADRA2A ADRA2C	4.59e-06	2	75	2	23400995
Pubmed	α2A- and α2C-adrenoceptor expression and functionality in postmortem prefrontal cortex of schizophrenia subjects.	ADRA2A ADRA2C	4.59e-06	2	75	2	34237656
Pubmed	Inhibition of insulin secretion via distinct signaling pathways in alpha2-adrenoceptor knockout mice.	ADRA2A ADRA2C	4.59e-06	2	75	2	14514350
Pubmed	Human Placenta Expresses α2-Adrenergic Receptors and May Be Implicated in Pathogenesis of Preeclampsia and Fetal Growth Restriction.	ADRA2A ADRA2C	4.59e-06	2	75	2	30273604
Pubmed	Common α2A and α2C adrenergic receptor polymorphisms do not affect plasma membrane trafficking.	ADRA2A ADRA2C	4.59e-06	2	75	2	24643471
Pubmed	Integrative effect of carvedilol and aerobic exercise training therapies on improving cardiac contractility and remodeling in heart failure mice.	ADRA2A ADRA2C	4.59e-06	2	75	2	23658728
Pubmed	An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling.	ADRA2A ADRA2C	4.59e-06	2	75	2	10948191
Pubmed	The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype.	ADRA2A ADRA2C	4.59e-06	2	75	2	16428542
Pubmed	Sympathetic alpha(2)-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload.	ADRA2A ADRA2C	4.59e-06	2	75	2	20083574
Pubmed	The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice.	ADRA2A ADRA2C	4.59e-06	2	75	2	17977919
Pubmed	Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.	ADRA2A ADRA2C	4.59e-06	2	75	2	19423370
Pubmed	Association study between Tourette's syndrome and polymorphisms of noradrenergic genes (ADRA2A, ADRA2C).	ADRA2A ADRA2C	4.59e-06	2	75	2	18075481
Pubmed	Molecular genetics of the human cytochrome P450 monooxygenase superfamily.	CYP2A13 CYP2C9 CYP2C18	1.07e-05	20	75	3	9890157
Pubmed	Genomic organization of adrenergic and serotonin receptors in the mouse: linkage mapping of sequence-related genes provides a method for examining mammalian chromosome evolution.	ADRA2A CYP2C9 ADRA2C	1.25e-05	21	75	3	1676978
Pubmed	The human CYP2C locus: a prototype for intergenic and exon repetition splicing events.	CYP2C9 CYP2C18	1.37e-05	3	75	2	10704292
Pubmed	Effect on diurnal intraocular pressure variation of eliminating the alpha-2 adrenergic receptor subtypes in the mouse.	ADRA2A ADRA2C	1.37e-05	3	75	2	18326714
Pubmed	Delayed transactivation of the receptor for nerve growth factor is required for sustained signaling and differentiation by alpha2-adrenergic receptors in transfected PC12 cells.	ADRA2A ADRA2C	1.37e-05	3	75	2	17215105
Pubmed	Distribution of mRNA encoding three alpha 2-adrenergic receptor subtypes in the developing mouse embryo suggests a role for the alpha 2A subtype in apoptosis.	ADRA2A ADRA2C	1.37e-05	3	75	2	9415717
Pubmed	Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities.	CYP2C9 CYP2C18	1.37e-05	3	75	2	15102943
Pubmed	Expression of alpha 2-adrenergic receptor subtypes in the mouse brain: evaluation of spatial and temporal information imparted by 3 kb of 5' regulatory sequence for the alpha 2A AR-receptor gene in transgenic animals.	ADRA2A ADRA2C	1.37e-05	3	75	2	8843087
Pubmed	Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine.	ADRA2A ADRA2C	1.37e-05	3	75	2	17261653
Pubmed	Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia.	DNAH5 DNAH9	1.37e-05	3	75	2	15750039
Pubmed	Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice.	ADRA2A ADRA2C	1.37e-05	3	75	2	17075569
Pubmed	Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine(7) receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with alpha(2) adrenergic receptors.	ADRA2A ADRA2C	1.37e-05	3	75	2	15026130
Pubmed	Acute heart failure with cardiomyocyte atrophy induced in adult mice by ablation of cardiac myosin light chain kinase.	A1CF MYLK3	1.37e-05	3	75	2	27025239
Pubmed	Alpha-adrenoceptor gene variants and autonomic nervous system function in a young healthy Japanese population.	ADRA2A ADRA2C	1.37e-05	3	75	2	17075692
Pubmed	Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice.	ADRA2A ADRA2C	1.37e-05	3	75	2	19125280
Pubmed	Haplotype-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene.	ADRA2A ADRA2C	1.37e-05	3	75	2	15592690
Pubmed	Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice.	ADRA2A ADRA2C	1.37e-05	3	75	2	10385696
Pubmed	Identification and analysis of axonemal dynein light chain 1 in primary ciliary dyskinesia patients.	DNAH5 DNAH9	1.37e-05	3	75	2	15845866
Pubmed	Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise.	ADRA2A ADRA2C	1.37e-05	3	75	2	26058836
Pubmed	Association between common genetic variants of α2A-, α2B-, and α2C-adrenergic receptors and ischemic stroke.	ADRA2A ADRA2C	1.37e-05	3	75	2	22560155
Pubmed	Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells.	ADRA2A ADRA2C	1.37e-05	3	75	2	12946937
Pubmed	Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission.	ADRA2A ADRA2C	1.37e-05	3	75	2	10647009
Pubmed	Resting sympathetic nerve activity is related to age, sex and arterial pressure but not to α2-adrenergic receptor subtype.	ADRA2A ADRA2C	1.37e-05	3	75	2	20613626
Pubmed	Nefopam but not physostigmine affects the thermoregulatory response in mice via alpha(2)-adrenoceptors.	ADRA2A ADRA2C	1.37e-05	3	75	2	19744502
Pubmed	Norepinephrine transporter knockout-induced up-regulation of brain alpha2A/C-adrenergic receptors.	ADRA2A ADRA2C	1.37e-05	3	75	2	16417582
Pubmed	Alpha2-adrenoceptors modulating neuronal serotonin release: a study in alpha2-adrenoceptor subtype-deficient mice.	ADRA2A ADRA2C	1.37e-05	3	75	2	11181434
Pubmed	Function of brain α2B-adrenergic receptor characterized with subtype-selective α2B antagonist and KO mice.	ADRA2A ADRA2C	1.37e-05	3	75	2	27751959
Pubmed	Insertion/insertion genotype of α(2B)-adrenergic receptor gene polymorphism is associated with silent myocardial ischemia in patients with type 2 diabetes mellitus.	ADRA2A ADRA2C	1.37e-05	3	75	2	20692245
Pubmed	Targeting adrenergic receptors to mitigate invariant natural killer T cells-induced acute liver injury.	ADRA2A ADRA2C	1.37e-05	3	75	2	37841583
Pubmed	Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice.	ADRA2A ADRA2C	1.37e-05	3	75	2	11927164
Pubmed	The Sympathetic Nervous System Mitigates CNS Autoimmunity via β2-Adrenergic Receptor Signaling in Immune Cells.	ADRA2A ADRA2C	1.37e-05	3	75	2	31533035
Pubmed	Association between Common Genetic Variants of α2A-, α2B-, and α2C-Adrenergic Receptors and Orthostatic Hypotension.	ADRA2A ADRA2C	1.37e-05	3	75	2	26427149
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome PH50IIC subfamily.	CYP2C9 CYP2C18	1.37e-05	3	75	2	8095407
Pubmed	Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of [alpha]2B adrenoceptors.	ADRA2A ADRA2C	1.37e-05	3	75	2	11125002
Pubmed	Genetic dissection of alpha2-adrenoceptor functions in adrenergic versus nonadrenergic cells.	ADRA2A ADRA2C	1.37e-05	3	75	2	19251826
Pubmed	Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes.	ADRA2A ADRA2C	1.37e-05	3	75	2	12764077
Pubmed	Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.64e-05	70	75	4	15128046
Pubmed	Murine chromosomal location of five bHLH-Zip transcription factor genes.	ADRA2A SPTA1 SERPINC1	1.89e-05	24	75	3	8530024
Pubmed	Cardiac MLC2 kinase is localized to the Z-disc and interacts with α-actinin2.	A1CF MYLK3	2.75e-05	4	75	2	31467300
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.	CYP2C9 CYP2C18	2.75e-05	4	75	2	2009263
Pubmed	Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.	CYP2C9 CYP2C18	2.75e-05	4	75	2	21798861
Pubmed	GGA3 Interacts with a G Protein-Coupled Receptor and Modulates Its Cell Surface Export.	ADRA2A GGA3	2.75e-05	4	75	2	26811329
Pubmed	Alpha2A- and alpha2C-adrenergic receptors form homo- and heterodimers: the heterodimeric state impairs agonist-promoted GRK phosphorylation and beta-arrestin recruitment.	ADRA2A ADRA2C	2.75e-05	4	75	2	16605244
Pubmed	Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.	ADRA2A ADRA2C	2.75e-05	4	75	2	19505981
Pubmed	An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions.	ADRA2A ADRA2C	2.75e-05	4	75	2	17971028
Pubmed	Biochemistry and molecular biology of the human CYP2C subfamily.	CYP2C9 CYP2C18	2.75e-05	4	75	2	7704034
Pubmed	Pharmacogenetics of low dose clonidine in irritable bowel syndrome.	ADRA2A ADRA2C	2.75e-05	4	75	2	19309415
Pubmed	Regulator of G protein signaling protein suppression of Galphao protein-mediated alpha2A adrenergic receptor inhibition of mouse hippocampal CA3 epileptiform activity.	ADRA2A ADRA2C	2.75e-05	4	75	2	19225179
Pubmed	Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response.	ADRA2A ADRA2C	2.75e-05	4	75	2	15920038
Pubmed	Novel murine homeo box gene on chromosome 1 expressed in specific hematopoietic lineages and during embryogenesis.	SPTA1 SERPINC1	2.75e-05	4	75	2	1672660
Pubmed	Roles of Hox genes: what we have learnt from gain of function and loss of function mutations in the mouse.	HOXD1 HOXA1	2.75e-05	4	75	2	7915637
Pubmed	The zeta isoform of 14-3-3 proteins interacts with the third intracellular loop of different alpha2-adrenergic receptor subtypes.	ADRA2A ADRA2C	2.75e-05	4	75	2	10224112
Pubmed	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.	CYP2C9 CYP2C18	2.75e-05	4	75	2	23755828
Pubmed	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	CYP2C9 CYP2C18	2.75e-05	4	75	2	19706858
Pubmed	DNAI2 mutations cause primary ciliary dyskinesia with defects in the outer dynein arm.	DNAH5 DNAH9	2.75e-05	4	75	2	18950741
Pubmed	Identification, tissue specific expression, and chromosomal localisation of several human dynein heavy chain genes.	DNAH10 DNAH9	2.75e-05	4	75	2	11175280
Pubmed	Candidate genes and sensory functions in health and irritable bowel syndrome.	ADRA2A ADRA2C	2.75e-05	4	75	2	18511740
Pubmed	Functional adrenergic receptor polymorphisms and idiopathic orthostatic intolerance.	ADRA2A ADRA2C	4.57e-05	5	75	2	15719258
Pubmed	Agonist-regulated Interaction between alpha2-adrenergic receptors and spinophilin.	ADRA2A ADRA2C	4.57e-05	5	75	2	11154706
Pubmed	DNAH11 Localization in the Proximal Region of Respiratory Cilia Defines Distinct Outer Dynein Arm Complexes.	DNAH5 DNAH9	4.57e-05	5	75	2	26909801
Pubmed	G(z) signaling: emerging divergence from G(i) signaling.	ADRA2A ADRA2C	4.57e-05	5	75	2	11313909
Pubmed	Interaction of the amyloid precursor like protein 1 with the alpha2A-adrenergic receptor increases agonist-mediated inhibition of adenylate cyclase.	ADRA2A ADRA2C	4.57e-05	5	75	2	16531006
Pubmed	ARMC4 mutations cause primary ciliary dyskinesia with randomization of left/right body asymmetry.	DNAH5 DNAH9	4.57e-05	5	75	2	23849778
Pubmed	The establishment of rotational polarity in the airway and ependymal cilia: analysis with a novel cilium motility mutant mouse.	DNAH5 DNAH9	4.57e-05	5	75	2	23525783
Pubmed	Interaction of the ubiquitin carboxyl terminal esterase L1 with alpha(2)-adrenergic receptors inhibits agonist-mediated p44/42 MAP kinase activation.	ADRA2A ADRA2C	4.57e-05	5	75	2	19477270
Pubmed	Double disruption of α2A- and α2C-adrenoceptors results in sympathetic hyperactivity and high-bone-mass phenotype.	ADRA2A ADRA2C	4.57e-05	5	75	2	20814988
Pubmed	A genome-wide association study of acenocoumarol maintenance dosage.	CYP2C9 CYP2C18	6.84e-05	6	75	2	19578179
Pubmed	Expression of adrenergic receptors in mouse preimplantation embryos and ovulated oocytes.	ADRA2A ADRA2C	6.84e-05	6	75	2	17636168
Pubmed	CFAP53 regulates mammalian cilia-type motility patterns through differential localization and recruitment of axonemal dynein components.	DNAH5 DNAH9	6.84e-05	6	75	2	33347437
Pubmed	A novel interaction between adrenergic receptors and the alpha-subunit of eukaryotic initiation factor 2B.	ADRA2A ADRA2C	6.84e-05	6	75	2	9235896
Pubmed	Placental alpha(2)-adrenoceptors control vascular development at the interface between mother and embryo.	ADRA2A ADRA2C	6.84e-05	6	75	2	12068299
Pubmed	α2-Adrenoceptor agonist dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5.	ADRA2A ADRA2C	6.84e-05	6	75	2	22933299
Cytoband	12q24.31	DNAH10 DHX37 ATP6V0A2	3.14e-04	80	75	3	12q24.31
GeneFamily	Dyneins, axonemal	DNAH10 DNAH5 DNAH9 DNAH14	1.30e-07	17	51	4	536
GeneFamily	Cytochrome P450 family 2	CYP2A13 CYP2C9 CYP2C18	1.30e-04	35	51	3	1001
GeneFamily	Adrenoceptors	ADRA2A ADRA2C	2.77e-04	9	51	2	169
GeneFamily	Aminoacyl tRNA synthetases, Class II	AARS1 FARS2	1.29e-03	19	51	2	132
Coexpression	GSE20151_CTRL_VS_FUSOBACT_NUCLEATUM_NEUTROPHIL_UP	ADRA2C GRB7 SERPINC1 ZFHX3 ZNF749 HS3ST2 PCBD1	1.62e-06	198	75	7	M4309
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PHLDB1 ARHGAP10 UNC5C ZFHX3 PRKG1 ADCY3	7.55e-07	187	75	6	86250acf088ec0c4800a0dfa031b0d4f7e52c342
ToppCell	T_cells-CD56_bright_CD16-_NK_cells\|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis	SH2D1B UNC5C ZFHX3 PRKG1 CHKA DNAH14	9.08e-07	193	75	6	826457e2aafdb61ead8a0a44d8cf9088d310684b
ToppCell	COVID-19-Epithelial_cells-Airway_mucous\|COVID-19 / group, cell type (main and fine annotations)	CYP2A13 DNAH10 CFAP61 DNAH5 DNAH9	5.69e-06	151	75	5	8216462e723fec2797387929dde095370947e10a
ToppCell	facs-Diaphragm-Limb_Muscle-24m\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DNAH10 SPTA1 MYO3B DNAH5 DNAH9	9.83e-06	169	75	5	12bdc709bc000d7f9061ecd9fbd57233eaacb7e2
ToppCell	T_cells-CD56_bright_CD16-_NK_cells\|World / Immune cells in Kidney/Urine in Lupus Nephritis	SH2D1B UNC5C PRKG1 CHKA DNAH14	1.07e-05	172	75	5	980e8b9e1ceeb0dec9eb9ef95c139e5ffe99b6e4
ToppCell	COVID-19-Heart-VSMC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ARHGAP10 UNC5C ZFHX3 PRKG1 ADCY3	1.16e-05	175	75	5	1125f0d3a5b2388fa77a820dea0288e824d84a82
ToppCell	Children_(3_yrs)-Mesenchymal-pericyte_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PHLDB1 ARHGAP10 UNC5C PRKG1 ADCY3	1.37e-05	181	75	5	451b87ac95154bb80018b8dd245b4a6389d81411
ToppCell	Adult-Mesenchymal-pericyte_cell-D122\|Adult / Lineage, Cell type, age group and donor	PHLDB1 ARHGAP10 UNC5C PRKG1 ADCY3	1.44e-05	183	75	5	fc31a43a637423cb3bb9aa184a3a889a0b9aaea6
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA4 DNAH10 SPTA1 DNAH5 DNAH9	1.48e-05	184	75	5	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA4 DNAH10 SPTA1 DNAH5 DNAH9	1.48e-05	184	75	5	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA4 DNAH10 SPTA1 DNAH5 DNAH9	1.48e-05	184	75	5	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 UNC5C ZFHX3 PRKG1 ADCY3	1.52e-05	185	75	5	51dfe6ac7df8b330343b37e3bee71e5c65267189
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 UNC5C ZFHX3 PRKG1 ADCY3	1.52e-05	185	75	5	a8c02cec3c414f3a0da9f2d6d28ce563b0030705
ToppCell	P28-Epithelial-airway_epithelial_cell-club_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	DNAH10 CFAP61 PCBD1 DNAH5 DNAH9	1.56e-05	186	75	5	a26811481668fa25c48a064a56c198685693ad8d
ToppCell	P28-Epithelial-airway_epithelial_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	DNAH10 CFAP61 PCBD1 DNAH5 DNAH9	1.56e-05	186	75	5	df80f101954b8ec6ccdb03e702de22e70b65181f
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_1-Pericyte\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PHLDB1 ARHGAP10 UNC5C PRKG1 ADCY3	1.73e-05	190	75	5	4eb92aef1ee868f4537483d19014d947b7684612
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PHLDB1 ARHGAP10 UNC5C PRKG1 ADCY3	1.73e-05	190	75	5	7be4341e2909101d756f14031c21e705eb45e69a
ToppCell	(12)_SLC16A7+\|World / shred by cell type by condition	TLR10 DNAH10 MYO3B DNAH5 DNAH9	1.77e-05	191	75	5	e427eeddd2e87c14376a37db0b43f120c90436bc
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 UNC5C ZFHX3 PRKG1 ADCY3	1.91e-05	194	75	5	ebb038f94f49f5c655578d1b018676e10c6b7e3c
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4/8-lo-Trm_Tgd\|GI_small-bowel / Manually curated celltypes from each tissue	CUL3 SH2D1B AKAP13 CHKA PHTF1	2.01e-05	196	75	5	5755ca4abcae3717894bbf7cbd49bca0a3a03067
ToppCell	COVID-19-lung-Pericytes/_Smooth_Muscle\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ARHGAP10 UNC5C ZFHX3 PRKG1 ADCY3	2.01e-05	196	75	5	754a3613340932563cd8424d775e18b93c3a1aaa
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4/8-lo\|GI_small-bowel / Manually curated celltypes from each tissue	CUL3 SH2D1B AKAP13 CHKA PHTF1	2.01e-05	196	75	5	181f3c1af565355b29f20ca6074147c313ca3477
ToppCell	Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_perivascular_immune_recruiting\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PHLDB1 ADRA2A ARHGAP10 PRKG1 ADCY3	2.11e-05	198	75	5	b7e900fc0a1b3fa5e47dcc36ce6b0c3ce6bf9739
ToppCell	cellseq2-Mesenchymal-Myocytic-Myocytic_2-VSMC\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ADRA2A ARHGAP10 ZFHX3 PRKG1 ADCY3	2.21e-05	200	75	5	fc802dd73f048881d9ddafd1b79ab3ca654510e2
ToppCell	cellseq2-Mesenchymal-Myocytic-Myocytic_2\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ADRA2A ARHGAP10 ZFHX3 PRKG1 ADCY3	2.21e-05	200	75	5	cffddb39960cd611428397c1ec4023192e8af5a7
ToppCell	cellseq2-Mesenchymal\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ADRA2A ARHGAP10 ZFHX3 PRKG1 ADCY3	2.21e-05	200	75	5	6b558cce0d6047c7e85f428adff80c5ca3084ea4
ToppCell	cellseq2-Mesenchymal-Myocytic\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ADRA2A ARHGAP10 ZFHX3 PRKG1 ADCY3	2.21e-05	200	75	5	e60aebd20be8012fa2febf6585ed34ebd64ec9b3
ToppCell	TCGA-Thymus-Primary_Tumor-Thymoma-Type_B3\|TCGA-Thymus / Sample_Type by Project: Shred V9	CYP4F8 CYP2C9 CFAP61 DNAH9	6.70e-05	129	75	4	c760a1f9b86f086074e6e04e50ab40da3639e5fb
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SPTA1 CFAP61 HS3ST2 HOXA1	8.46e-05	137	75	4	761cc0e2b4971e98f6d0691d4575b5cd208b602d
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L6b\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	SAMD9L ADRA2A GRB7 HS3ST2	9.45e-05	141	75	4	5ef3166c5271aa90fd0633016edfe2c74b835319
ToppCell	LPS-antiTNF-Epithelial_airway-Ciliated_cells-Ciliated\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DNAH10 CFAP61 DNAH5 DNAH9	1.14e-04	148	75	4	d61123f0c811287843d066b932b4a9ff09c07c5b
ToppCell	LPS-antiTNF-Epithelial_airway-Ciliated_cells\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DNAH10 CFAP61 DNAH5 DNAH9	1.14e-04	148	75	4	c8e93b87212f55774223caa385859c566fa1981f
ToppCell	BAL-Mild-Myeloid-cDC-cDC-cDC_3\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	TLR10 CHKA MAGEF1 MGAM2	1.23e-04	151	75	4	0b6b37734430918378ed94e40877f0c4ae9b25ec
ToppCell	BAL-Mild-Myeloid-cDC-cDC-cDC_3\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	TLR10 CHKA MAGEF1 MGAM2	1.23e-04	151	75	4	30225a1a7800b0ae19e16ac164f561379eedb99d
ToppCell	Control-Epithelial_airway-Ciliated_cells-Ciliated\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DNAH10 CFAP61 DNAH5 DNAH9	1.33e-04	154	75	4	4e3bc24043144143842627cacf6f90dda2228910
ToppCell	Control-Epithelial_airway-Ciliated_cells\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DNAH10 CFAP61 DNAH5 DNAH9	1.33e-04	154	75	4	7556a4b2b062da5ae7ec2bbb66e745e7662db628
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DNAH10 CFAP61 DNAH5 DNAH9	1.36e-04	155	75	4	5f1e2195a6b831e1b636f5cc3a282ca423721822
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells-Ciliated\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DNAH10 CFAP61 DNAH5 DNAH9	1.36e-04	155	75	4	0944429459f642a1bcc56edc1ec28aaecde3e2dc
ToppCell	10x5'v1-week_12-13-Myeloid_DC-DC-DC2\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	AP2S1 DNAH10 CCR5 SAMHD1	1.40e-04	156	75	4	03f3c5ffb27758fe63797143fcc938f9e8a4e10d
ToppCell	TCGA-Endometrium-Primary_Tumor-Endometrial_Adenocarcinoma-Serous_adenocarcinoma-3\|TCGA-Endometrium / Sample_Type by Project: Shred V9	CYP2C9 CYP2C18 ZPLD1 GRB7	1.43e-04	157	75	4	ef70abc999be3a2c1eed7d21aef4b484f69d8567
ToppCell	AT1-AT2_cells-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	CYP2C9 ABCA4 MYO3B DNAH5	1.47e-04	158	75	4	3bc51cfd37b289cc3e866b54ce55a298e5eff690
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DNAH10 UNC5C FSHR DNAH9	1.54e-04	160	75	4	c381ec6be8cf887861cc18f831a20db42f953fe1
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DNAH10 UNC5C FSHR DNAH9	1.54e-04	160	75	4	25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585
ToppCell	5'-Adult-SmallIntestine-Hematopoietic-T_cells-TRGV4_gdT\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SH2D1B AKAP13 CCR5 PHTF1	1.65e-04	163	75	4	11cc18f36604d9a5f4e7fb8626a8f0fb141da5e1
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	NLRP10 UNC5C PRKG1 ADCY3	1.69e-04	164	75	4	f6a961fa2002da7d9679f32af99e1314c0593ef9
ToppCell	saliva-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	AARS1 PHF14 CCR5 DNAH9	1.69e-04	164	75	4	d8ecb3de6e34f5f574449e3d2f26fa0b2b7e84e8
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN2(Gad1Gad2)-Cplx3-Inhibitory_Neuron.Gad1Gad2.Cplx3-Npy_(Cortical_subplate_interneuron)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	DNAH10 MYO3B SIAH3	1.72e-04	64	75	3	28acc0d394b8cd2fd93ae5e0801f0ff1dd4b16ac
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN2(Gad1Gad2)-Cplx3-Inhibitory_Neuron.Gad1Gad2.Cplx3-Npy_(Cortical_subplate_interneuron)-\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	DNAH10 MYO3B SIAH3	1.72e-04	64	75	3	61414e0fa2242f156f0f45f8733b831b7f965dd8
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 UNC5C PRKG1 ADCY3	1.73e-04	165	75	4	4f83ac71efc57be3668d8db1e62bad05dc6a5e2b
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 UNC5C PRKG1 ADCY3	1.73e-04	165	75	4	cd8de98af8a1a8a6c81d71fae807cc07f319f4c9
ToppCell	3'-Child04-06-SmallIntestine-Hematopoietic-T_cells-TRGV4_gdT\|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SH2D1B CCR5 ZNF749 SIAH3	1.73e-04	165	75	4	9f6f3a614ac614488e9f59cf2805467ff075ccca
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	SYNJ1 ARHGAP10 ZNF749 CFAP61	1.81e-04	167	75	4	abc4ba308ca3be41b0da604f5d82579fd58dff7b
ToppCell	E16.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated-Ciliated_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	DNAH10 CFAP61 DNAH5 DNAH9	1.85e-04	168	75	4	fa7c0303918cea04e3f4c4f3cb079be19004d214
ToppCell	E16.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Ciliated\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	DNAH10 CFAP61 DNAH5 DNAH9	1.85e-04	168	75	4	7edcab103c69e928d5c19a0d218ffb3ae32f9e70
ToppCell	5'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MYLK3 DNAH10 CFAP61 DNAH9	1.90e-04	169	75	4	fba841664939c771881ba97f14ef1df6635c04ff
ToppCell	TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-6\|TCGA-Liver / Sample_Type by Project: Shred V9	UNC5C FSHR PRKG1 ADCY3	1.90e-04	169	75	4	e992530776cab922d0360b275fb9cb8bd0017b06
ToppCell	RA-01._Fibroblast_I\|RA / Chamber and Cluster_Paper	PHLDB1 UNC5C ZFHX3 SAMHD1	1.90e-04	169	75	4	6373562ab3b1765060212a6a53d6543e7e942e80
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2-Exc_L3-5_RORB_HSPB3\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MYLK3 ARHGAP10 FSHR DNAH5	1.94e-04	170	75	4	985c6c9e3c593ed0628a481f06c2c91b2ab5d746
ToppCell	3'-GW_trimst-2-SmallIntestine-Epithelial-neuro-epithelial-EECs\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A1CF CYP2C18 GRB7 PCBD1	1.94e-04	170	75	4	fcaa32607bcbd8be6f040f9487c3d71e976e1077
ToppCell	3'-Child09-12-SmallIntestine-Hematopoietic-T_cells-TRGV4_gdT\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	LARGE2 NBAS SH2D1B PHTF1	1.94e-04	170	75	4	65c7ed586e7615203a59999549892ed466a89502
ToppCell	Control-Fibroblasts-Pericytes\|Control / group, cell type (main and fine annotations)	ARHGAP10 UNC5C PRKG1 ADCY3	1.98e-04	171	75	4	080003f698f867935c2bfc55d241d3650f45a0ab
ToppCell	wk_08-11-Epithelial-Proximal_epithelial-Deuterosomal\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	CYP2A13 DNAH10 DNAH5 DNAH9	2.03e-04	172	75	4	08ad76412c9cc3504141797b44b88478ced87476
ToppCell	TCGA-Head_and_Esophagus-Solid_Tissue_Normal-Head_and_Neck-Head_and_Neck_normal_tissue-5\|TCGA-Head_and_Esophagus / Sample_Type by Project: Shred V9	CYP2A13 DNAH10 SH2D1B DNAH9	2.03e-04	172	75	4	6b8a8d3b97c10b9d092307eed3cacbd2745df185
ToppCell	facs-Diaphragm-Limb_Muscle-24m-Mesenchymal\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DNAH10 MYO3B DNAH5 DNAH9	2.07e-04	173	75	4	66f37c1437705734b20601656fa4aa1d92ca30be
ToppCell	facs-Diaphragm-Limb_Muscle-24m-Mesenchymal-nan\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DNAH10 MYO3B DNAH5 DNAH9	2.07e-04	173	75	4	649b08a409095592cccf31883be69c754411280d
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2-Exc_L6_FEZF2_CPZ\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CIB2 SH2D1B ZFHX3 HS3ST2	2.12e-04	174	75	4	ccc59416548ed3b783fd7a050ab32076c4296254
ToppCell	COVID-19-kidney-PCT-S3-2\|kidney / Disease (COVID-19 only), tissue and cell type	A1CF CYP2C9 CYP2C18 SERPINC1	2.12e-04	174	75	4	5aa2fb631505600f37d2b87b02def7be139dc262
ToppCell	5'-GW_trimst-2-SmallIntestine-Epithelial-mature_enterocytic-Paneth\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	LARGE2 GRB7 PCBD1 MGAM2	2.17e-04	175	75	4	bffa623511ceb0b9bf76d87f9a10cfadfe0e940f
ToppCell	PCW_13-14-Epithelial-Epithelial_ciliated\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DNAH10 CFAP61 DNAH5 DNAH9	2.17e-04	175	75	4	b1369d2b74f461e6822d0c33e9b50fe0dfbceb54
ToppCell	PCW_13-14-Epithelial-Epithelial_ciliated-epi_ciliated_(14)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DNAH10 CFAP61 DNAH5 DNAH9	2.17e-04	175	75	4	c82ec6deb6ccdd991a69a62b6d62d5b14c803d7a
ToppCell	Ciliated_cells-A-Donor_02\|World / lung cells shred on cell class, cell subclass, sample id	ADRA2A MYLK3 DNAH10 DNAH9	2.21e-04	176	75	4	1c364155f46b9a7c995bdc2cc2333c437cd90f5b
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SH2D1B AKAP13 ZFHX3 HS3ST2	2.21e-04	176	75	4	72a2a01618ce836bc843395d5095e9090759b4a6
ToppCell	COVID-19-kidney-PCT-S3-2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	A1CF CYP2C9 CYP2C18 SERPINC1	2.21e-04	176	75	4	b6497324e3e52f514ce556a3fa0c3011c45dcc7b
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 UNC5C PRKG1 ADCY3	2.26e-04	177	75	4	4943d040eee0f9dceaddc7498171281d170e271f
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 UNC5C PRKG1 ADCY3	2.26e-04	177	75	4	3f2272b577c862dba8ccfb41184054bbd0ace6f5
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ARHGAP10 UNC5C PRKG1 ADCY3	2.26e-04	177	75	4	452ec2df36c6d656a7cdadc55be545ccdb146a29
ToppCell	Fetal_29-31_weeks-Epithelial-ciliated_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DNAH10 CFAP61 DNAH5 DNAH9	2.31e-04	178	75	4	de5d50d7ca9ee9eb62f50c88a0c6d47f0694b2e6
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-kidney_interstitial_fibroblast_5\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 SAMHD1 PRKG1 ADCY3	2.31e-04	178	75	4	d4ecb84e9b1f4ec49c519321156aa10f9bd34cce
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_5-Exc_L4-5_RORB_LINC01474\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ABCA4 FSHR GRB7 HS3ST2	2.31e-04	178	75	4	5522b179c2e7dd707de01e2df10556349d0382a6
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_5-Exc_L4-5_RORB_LINC01474\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ABCA4 FSHR GRB7 HS3ST2	2.31e-04	178	75	4	f7f88879a05b2b5fa92cf5317b76f7a3064d1358
ToppCell	3'-GW_trimst-1-SmallIntestine-Epithelial-epithelial_progenitor_cell-CLDN10+_cells\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	LARGE2 ADRA2A ZPLD1 CFAP61	2.36e-04	179	75	4	7eca1e19ae6b5b1f18c721691dc3e860705628f2
ToppCell	5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.3.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ARHGAP10 UNC5C PRKG1 ADCY3	2.36e-04	179	75	4	dc6cd46fa652b296ddbc41855f6377946d0a4cdc
ToppCell	COVID-19-Heart-VSMC\|Heart / Disease (COVID-19 only), tissue and cell type	UNC5C ZFHX3 PRKG1 ADCY3	2.36e-04	179	75	4	a69ad6912b5c10bb9f9d800f724c792341e9bab1
ToppCell	RA-01._Fibroblast_I\|World / Chamber and Cluster_Paper	PHLDB1 UNC5C ZFHX3 SAMHD1	2.46e-04	181	75	4	2b6ddeb53a79a658e2ba78527ff48c155b20daa6
ToppCell	facs-Marrow-KLS-18m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PHLDB1 NLRP10 UNC5C GRB7	2.46e-04	181	75	4	35eefd874a892eaf21f24fdce89e7ea3b8ee285f
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Epithelial-Tuft-related\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ADRA2A A1CF DNAH10 MGAM2	2.46e-04	181	75	4	1c04e53f46992a0aea9d3eee985681ec4e71f80d
ToppCell	COVID-19-Heart-Pericyte\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ARHGAP10 UNC5C PRKG1 ADCY3	2.46e-04	181	75	4	33cac65ed1ea5e7bd72250495df4f850b143d5aa
ToppCell	5'-GW_trimst-1-SmallIntestine-Epithelial-epithelial_progenitor_cell-Stem_cells\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CYP2A13 HOXD1 GRB7 CFAP61	2.46e-04	181	75	4	c7a220891567c7539ad5a9ac9db375f0de08ea00
ToppCell	facs-Marrow-KLS-18m-Lymphocytic-naive_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PHLDB1 NLRP10 UNC5C GRB7	2.46e-04	181	75	4	e4c3e0eae9f21e78b5dd18cf017bd041ffc8c968
ToppCell	Fetal_29-31_weeks-Epithelial-ciliated_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DNAH10 CFAP61 DNAH5 DNAH9	2.46e-04	181	75	4	dfce05bd472f67e6e2bb60ebd6fd34f0a9aeeca6
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Epithelial-Tuft-related-BEST4+_epithelial\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ADRA2A A1CF DNAH10 MGAM2	2.46e-04	181	75	4	83adf61f44cebe9e75de175c5dc39237fbf9ed24
ToppCell	RA-07._Pericyte\|World / Chamber and Cluster_Paper	ARHGAP10 UNC5C PRKG1 ADCY3	2.52e-04	182	75	4	2075efeae633550fb2eb026d0dfd741c8252482e
ToppCell	Control-Epithelial_cells-Airway_ciliated\|Control / group, cell type (main and fine annotations)	DNAH10 CFAP61 DNAH5 DNAH9	2.52e-04	182	75	4	fb725d10d9ed25dfc6d5bb69cfef78513f7d3e8f
ToppCell	Ciliated_cells-B-SSc-ILD_02\|World / lung cells shred on cell class, cell subclass, sample id	MYLK3 DNAH10 DNAH5 DNAH9	2.52e-04	182	75	4	e44c4810dc7d51a76b86d7623f8e4c4d8b4bf2fc
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_5\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ABCA4 FSHR GRB7 HS3ST2	2.57e-04	183	75	4	b5d041d0a3506c33de72bf14fa0443f4410fddf1
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_B-B_cell\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	TLR10 LARGE2 SP100 SAMD9L	2.57e-04	183	75	4	f4f453692da77cef666cc281c4883c9c6b279fd4
ToppCell	3'-Distal_airway-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DNAH10 CFAP61 DNAH5 DNAH9	2.57e-04	183	75	4	58847e8f3a7ce3e33adba9477bcd55e769a64a90
ToppCell	droplet-Thymus-nan-18m-Myeloid-Plasma_cells_and_B_cells\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LARGE2 CACNA1S CIB2 PCBD1	2.57e-04	183	75	4	ffb1bbbccb34d1a7e99872611f497450039d5019
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_B-B_cell-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	TLR10 LARGE2 SP100 SAMD9L	2.57e-04	183	75	4	6086a862ab35bc683af44c03ee14cbb08ab99945
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ARHGAP10 UNC5C PRKG1 ADCY3	2.57e-04	183	75	4	667717366cb181b8a04a347e64f0f5a4dfc6ee7f
Drug	4-bromophenol	SP100 CYP2A13 CYP4F8 CYP2C9 CYP2C18 AKAP13	1.07e-07	70	74	6	CID000007808
Drug	1,1-dichloroethylene	CYP2A13 CYP4F8 CYP2C9 CYP2C18 DNAH9	1.50e-06	60	74	5	CID000006366
Drug	C14845	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.70e-06	27	74	4	CID011954064
Drug	BP-9,10-oxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.70e-06	27	74	4	CID000037456
Drug	Brn 4136738	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.70e-06	27	74	4	CID000050331
Drug	9-OH-BaP-4,5-oxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.98e-06	28	74	4	CID000115064
Drug	11-H-14,15-EETA	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.64e-06	30	74	4	CID011954058
Drug	19-hydroxytestosterone	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.64e-06	30	74	4	CID000150968
Drug	BP-7,8-oxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	3.45e-06	32	74	4	CID000037455
Drug	12(13)-EpOME	CYP2A13 CYP4F8 CYP2C9 CYP2C18	4.43e-06	34	74	4	CID000001416
Drug	TCEO	CYP2A13 CYP4F8 CYP2C9 CYP2C18	4.43e-06	34	74	4	CID000028167
Drug	AC1O5XSP	CYP2A13 CYP4F8 CYP2C9 CYP2C18	4.43e-06	34	74	4	CID006442739
Drug	AC1L1CJI	CYP2A13 CYP4F8 CYP2C9 CYP2C18	4.99e-06	35	74	4	CID000001929
Drug	D-702	CYP2A13 CYP2C9 CYP2C18	5.34e-06	11	74	3	CID000054077
Drug	15-H-11,12-EETA	CYP2A13 CYP4F8 CYP2C9 CYP2C18	5.60e-06	36	74	4	CID011954042
Drug	AC1L3NGJ	CYP2A13 CYP4F8 CYP2C9 CYP2C18	5.60e-06	36	74	4	CID000092121
Drug	11,14,15-THET	CYP2A13 CYP4F8 CYP2C9 CYP2C18	7.76e-06	39	74	4	CID006439531
Drug	11,12,15-trihydroxyeicosatrienoic acid	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.05e-05	42	74	4	CID006439610
Drug	polybrominated biphenyl	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.26e-05	44	74	4	CID000042948
Drug	tienilic acid	CYP2A13 CYP4F8 CYP2C9 CYP2C18 ADCY3	1.32e-05	93	74	5	CID000038409
Drug	naphthalene-1,2-dihydrodiol	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.38e-05	45	74	4	CID000000362
Drug	C14802	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.65e-05	47	74	4	CID011954053
Drug	C14800	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.79e-05	48	74	4	CID011954051
Drug	nitro-L	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.79e-05	48	74	4	CID000006849
Drug	AC1L1KIN	CYP2A13 CYP4F8 CYP2C9 CYP2C18 SERPINC1	1.87e-05	100	74	5	CID000005516
Drug	19-HETE	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.95e-05	49	74	4	CID006439528
Drug	bromobenzene-3,4-oxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.95e-05	49	74	4	CID000108121
Drug	bromobenzene-2,3-oxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.11e-05	50	74	4	CID003036760
Drug	6-hydroxymelatonin	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.11e-05	50	74	4	CID000001864
Drug	1,1-dichloroethylene epoxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.11e-05	50	74	4	CID000119521
Drug	naphthalene epoxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.29e-05	51	74	4	CID000108063
Drug	D 703	CYP2A13 CYP2C9 CYP2C18	2.60e-05	18	74	3	CID000054088
Drug	9-hydroxybenzo(a)pyrene	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.67e-05	53	74	4	CID000028598
Drug	dichloroacetaldehyde	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.87e-05	54	74	4	CID000006576
Drug	17-AAG; Up 200; 1uM; HL60; HT_HG-U133A	PHLDB1 CYP2C9 ADRA2C PCBD1 PLOD1 PHTF1	2.92e-05	183	74	6	6166_UP
Drug	verapamil	CACNA1S CYP2A13 ADRA2A CYP2C9 ABCA4 CYP2C18 MYO3B KCNS1 ADCY3	2.94e-05	490	74	9	CID000002520
Drug	D 617	CYP2A13 CYP2C9 CYP2C18	3.08e-05	19	74	3	CID000093168
Drug	chloroacetyl chloride	CYP2A13 CYP4F8 CYP2C9 CYP2C18	3.09e-05	55	74	4	CID000006577
Drug	Clonidine	ADRA2A ADRA2C	3.12e-05	3	74	2	DB00575
Drug	Brimonidine	ADRA2A ADRA2C	3.12e-05	3	74	2	DB00484
Drug	Tizanidine	ADRA2A ADRA2C	3.12e-05	3	74	2	DB00697
Drug	1,2-dihydroxynaphthalene	CYP2A13 CYP4F8 CYP2C9 CYP2C18	3.56e-05	57	74	4	CID000011318
Drug	bromoacetaldehyde	CYP2A13 CYP4F8 CYP2C9 CYP2C18	3.82e-05	58	74	4	CID000105131
Drug	ICI 182,780; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA	FARS2 OSGEPL1 ZBTB25 GRB7 AKAP13 IP6K2	3.83e-05	192	74	6	1076_UP
Drug	AC1Q7AUJ	CYP2A13 CYP4F8 CYP2C9 CYP2C18 SAMHD1	3.99e-05	117	74	5	CID000003303
Drug	Glimepiride [93479-97-1]; Up 200; 8.2uM; PC3; HT_HG-U133A	CIB2 A1CF AP2S1 ADRA2C PRKG1 CHKA	4.06e-05	194	74	6	6628_UP
Drug	benzphetamine	CYP2A13 CYP4F8 ADRA2A CYP2C9 CYP2C18	4.33e-05	119	74	5	CID000002341
Drug	Oxprenolol hydrochloride [6452-73-9]; Down 200; 13.2uM; HL60; HT_HG-U133A	CUL3 A1CF SYNJ1 KCNS1 AKAP13 MAGEF1	4.42e-05	197	74	6	6145_DN
Drug	Flecainide acetate [54143-56-5]; Down 200; 8.4uM; MCF7; HT_HG-U133A	SP100 AP2S1 ZBTB25 AKAP13 CHKA ADCY3	4.54e-05	198	74	6	3418_DN
Drug	BP-4,5-oxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	4.66e-05	61	74	4	CID000037786
Drug	Amyleine hydrochloride [532-59-2]; Up 200; 14.8uM; HL60; HG-U133A	PHLDB1 CIB2 HOXD1 OSGEPL1 AKAP13 ATP6V0A2	4.67e-05	199	74	6	1991_UP
Drug	tizanidine	ADRA2A CYP2C9 ATP6V0A2	5.57e-05	23	74	3	CID000005487
Drug	2-methoxyidazoxan	ADRA2A ADRA2C	6.23e-05	4	74	2	ctd:C058525
Drug	Bethanidine	ADRA2A ADRA2C	6.23e-05	4	74	2	DB00217
Drug	McN-5691	CACNA1S ADRA2A	6.23e-05	4	74	2	CID000127269
Drug	4-((4-bromophenyl)-(ethoxyimino)methyl)-1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl-1,4'-bipiperidine N-oxide	CYP2C9 CCR5	6.23e-05	4	74	2	ctd:C438583
Drug	propoxyphene	CYP2A13 CYP4F8 CYP2C9 CYP2C18	6.75e-05	67	74	4	CID000010100
Drug	piperonyl butoxide	CYP2A13 CYP4F8 CYP2C9 CYP2C18	6.75e-05	67	74	4	CID000005794
Drug	5,6-epoxyeicosatrienoic acid	CYP2A13 CYP4F8 CYP2C9 CYP2C18	7.15e-05	68	74	4	CID000001778
Drug	8-bromoadenosine	FSHR PRKG1 CHKA PLOD1 ADCY3	7.36e-05	133	74	5	CID000096544
Drug	8(9)-EET	CYP2A13 CYP4F8 CYP2C9 CYP2C18	7.57e-05	69	74	4	CID000001901
Drug	1,2-dibromoethane	CYP2A13 CYP4F8 CYP2C9 CYP2C18	8.47e-05	71	74	4	CID000007839
Drug	carteolol	CYP2A13 CYP4F8 CYP2C9 CYP2C18	8.95e-05	72	74	4	CID000002583
Drug	DDS-NOH	AARS1 CYP2C9 CYP2C18	9.11e-05	27	74	3	CID000065387
Drug	2,2,2-trichloroethanol	CYP2A13 CYP4F8 CYP2C9 CYP2C18	9.44e-05	73	74	4	CID000008259
Drug	chloral	CYP2A13 CYP4F8 CYP2C9 CYP2C18	9.44e-05	73	74	4	CID000006407
Drug	norverapamil	CYP2A13 CYP2C9 CYP2C18	1.02e-04	28	74	3	CID000104972
Drug	Ne-Boc-L-lysine	AARS1 FARS2	1.04e-04	5	74	2	CID000151005
Drug	Fenoldopam	ADRA2A ADRA2C	1.04e-04	5	74	2	DB00800
Drug	NSC9700	CYP2A13 CYP4F8 CYP2C9 ABCA4 CYP2C18 MYO3B FSHR PLOD1 ADCY3	1.05e-04	578	74	9	CID000005408
Drug	tolazoline	ADRA2A ADCY3 ATP6V0A2	1.13e-04	29	74	3	CID000005504
Drug	C20H32O4	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.22e-04	78	74	4	CID000001440
Drug	BP-7,8-diol	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.22e-04	78	74	4	CID000025892
Drug	trimipramine	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.35e-04	80	74	4	CID000005584
Drug	walrycin A	CYP2A13 CYP4F8 CYP2C18	1.53e-04	32	74	3	ctd:C574123
Drug	Xylometazoline	ADRA2A ADRA2C	1.55e-04	6	74	2	DB06694
Drug	4',5-dihydroxydiclofenac	CYP2C9 CYP2C18	1.55e-04	6	74	2	CID003052567
Drug	mono-OH	CYP2C9 CYP2C18	1.55e-04	6	74	2	CID000183679
Drug	Phenoxybenzamine	ADRA2A ADRA2C	1.55e-04	6	74	2	DB00925
Drug	3'-hydroxydiclofenac	CYP2C9 CYP2C18	1.55e-04	6	74	2	CID000112230
Drug	diosmetin	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.71e-04	85	74	4	CID005281612
Drug	arabinosyladenine	AARS1 ADRA2A MYLK3 FARS2 SPTA1 SERPINC1 PRKG1 IDH3B CHKA ADCY3	1.72e-04	762	74	10	CID000000191
Drug	trichloroethylene	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.95e-04	88	74	4	CID000006575
Drug	mephenytoin	CYP2A13 CYP4F8 CYP2C9 CYP2C18	1.95e-04	88	74	4	CID000004060
Drug	14(15)-EpETrE	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.04e-04	89	74	4	CID000001431
Drug	Lurasidone Hydrochloride	ADRA2A ADRA2C	2.17e-04	7	74	2	ctd:D000069056
Drug	xylometazoline	ADRA2A ADRA2C	2.17e-04	7	74	2	ctd:C009695
Drug	parathion	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.22e-04	91	74	4	CID000000991
Drug	felodipine	CACNA1S CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.26e-04	169	74	5	CID000003333
Drug	p-nitroanisole	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.31e-04	92	74	4	CID000007485
Drug	2-naphthol	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.41e-04	93	74	4	CID000008663
Drug	AC1L1BEQ	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.41e-04	93	74	4	CID000001407
Drug	lansoprazole	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.41e-04	93	74	4	CID000003883
Drug	17-AAG; Up 200; 1uM; HL60; HT_HG-U133A	ZBTB25 KCNS1 PCBD1 PLOD1 PHTF1	2.45e-04	172	74	5	1159_UP
Drug	IC261	DNAH10 CHKA DNAH5 DNAH9	2.72e-04	96	74	4	CID000003674
Drug	bromobenzene	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.83e-04	97	74	4	CID000007961
Drug	Oxymetazoline	ADRA2A ADRA2C	2.88e-04	8	74	2	ctd:D010109
Drug	clobazam	CYP2C18 SERPINC1	2.88e-04	8	74	2	ctd:C012255
Drug	propafenone	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.95e-04	98	74	4	CID000004932
Drug	PCB 77	CYP2A13 CYP4F8 CYP2C9 CYP2C18	2.95e-04	98	74	4	CID000036187
Disease	X-21258 measurement	CYP2C9 CYP2C18	1.81e-05	3	73	2	EFO_0800802
Disease	microcephaly (implicated_via_orthology)	AARS1 DHX37 CHKA	6.84e-05	32	73	3	DOID:10907 (implicated_via_orthology)
Disease	multiple sclerosis	PHLDB1 ZPLD1 GRB7 AKAP13 ZFHX3 HS3ST2 ADCY3 HOXA1	1.10e-04	594	73	8	MONDO_0005301
Disease	glycine conjugate of C10H14O2 (1) measurement	CYP2C9 CYP2C18	1.26e-04	7	73	2	EFO_0800655
Disease	hypertension (biomarker_via_orthology)	CYP4F8 ADRA2A CYP2C18 CCR5 PRKG1	2.53e-04	227	73	5	DOID:10763 (biomarker_via_orthology)
Disease	gamma-glutamylleucine measurement	FARS2 PRKG1	4.63e-04	13	73	2	EFO_0021140
Disease	Situs ambiguus	DNAH5 DNAH9	6.21e-04	15	73	2	C0266642
Disease	metabolonic lactone sulfate measurement	CYP2C9 CYP2C18	1.00e-03	19	73	2	EFO_0800659
Disease	visceral adipose tissue measurement, body mass index	NBAS DNAH10 SIK3	1.33e-03	87	73	3	EFO_0004340, EFO_0004765
Disease	platelet reactivity measurement, response to clopidogrel	CYP2C18 SYNJ1	1.48e-03	23	73	2	EFO_0004985, GO_1903493
Disease	lobe attachment	CACNA1S CYP2A13 MYO3B SIK3	1.75e-03	207	73	4	EFO_0007667
Disease	susceptibility to pneumonia measurement	UNC5C ADCY3 DNAH14	1.81e-03	97	73	3	EFO_0008410
Disease	hepatitis C (is_implicated_in)	CCR5 SAMHD1	2.19e-03	28	73	2	DOID:1883 (is_implicated_in)
Disease	R-6-hydroxywarfarin to R-warfarin ratio measurement	CYP2C9 ZPLD1 UNC5C	2.33e-03	106	73	3	EFO_0803333
Disease	mammographic density percentage	PRKG1 ADCY3	2.35e-03	29	73	2	EFO_0006502

Protein segments in the cluster

Peptide	Gene	Start	Entry
IFRHYTKFFLKEILR	CFAP61	566	Q8NHU2
RVKKIRDYAFVHFSN	A1CF	261	Q9NQ94
KNFKHRAYASLFREL	ABCA4	1236	P78363
IYTVFNQDFRRSFKH	ADRA2C	436	P18825
FKDLYAKDKRFQAFV	AKAP13	2111	Q12802
IHFFFAKLNCRLYRK	SERPINC1	151	P01008
GEKFRNYLLVFFQKH	CCR5	301	P51681
NYLLVFFQKHIAKRF	CCR5	306	P51681
DRAFHTFKKQRDVFY	CDAN1	446	Q8IWY9
HTNFVEFRNFKIIYR	AP2S1	46	P53680
RVKKLRDYAFVHFFN	RBM46	266	Q8TBY0
LRVKNKHVEFFRNFY	LARGE2	346	Q8N3Y3
KHVEFFRNFYLTFLE	LARGE2	351	Q8N3Y3
AQRKFAHSLRDFKFE	ARHGAP10	56	A1A4S6
KRKVYEFLRSFNFHP	OSGEPL1	16	Q9H4B0
FLGIKRFITDKHFYF	HS3ST2	291	Q9Y278
RYVFGFELKQFDRKH	MAGEF1	126	Q9HAY2
RFHFKITDFNNIRYE	MGAM2	136	Q2M2H8
KEALFQFFHNGRYLR	IP6K2	286	Q9UHH9
KEFHFNKYLTRARRI	HOXD1	246	Q9GZZ0
LAIKKFYSFRHISFQ	NLRP10	456	Q86W26
ARRYGDFFIRQIHKF	EIF3L	536	Q9Y262
YRSFHDLRQAFRKFT	PRKG1	71	Q13976
RDAIFKQFHFKDFNR	PCBD1	31	P61457
KHFYVVTAANRLRKF	MYLK3	801	Q32MK0
AYDKNGFRILFHFAK	GGA3	601	Q9NZ52
IFNKFSHFYRRQKAL	KCNS1	456	Q96KK3
KEFHFNKYLTRARRV	HOXA1	246	P49639
RYDAEFFKKFRNQNI	NBAS	711	A2RRP1
FFAYCKQHADRLDRK	PHF14	491	O94880
DSRFVFRKNFAKYEL	GRB7	176	Q14451
FRRFKRSAQFFNYKI	PLOD1	41	Q02809
RFEFYERAKKAFAVV	FUOM	116	A2VDF0
RAKSQRIAKFAFDYA	IDH3B	191	O43837
AHRVNKDTKFRDFFL	CYP2A13	371	Q16696
RCIQDFFKKHIQYKF	CDC123	211	O75794
GKFYATFLIQEHFRK	CACNA1S	1521	Q13698
AQARFDAYFHQKRKL	CHKA	441	P35790
AFEIFRRFYLAKHSG	CUL3	531	Q13618
LVVKRNNQFFRYKDF	CYP4F8	231	P98187
TFLHFQRKEFFAKLR	FASTKD1	386	Q53R41
ELFARFDKLAAKYHQ	ADCY3	346	O60266
LSFFQKRIYKNLHIF	DNAH14	2126	Q0VDD8
VIFHDRFDYKDQRFL	CYP2C18	181	P33260
DVVFFIQHFCLYRKR	CTNS	346	O60931
IKFHYIFNLRDFANI	DNAH9	2671	Q9NYC9
IIFHKRFDYKDQQFL	CYP2C9	181	P11712
YAIFTKNFRRDFFIL	FSHR	626	P23945
YKHFARFLLEGQVFR	DHX37	1061	Q8IY37
FHFFRNKEVDYKIPV	DNAH10	4121	Q8IVF4
AKFHYVFNLRDLSRV	DNAH5	2786	Q8TE73
IDFNEFLKAFYVVHR	PPEF1	626	O14829
RLRNYFKKEELNFTH	UTP25	626	Q68CQ4
EKQFLLFTERFHFYK	UTP25	661	Q68CQ4
EQLKRNVRFHAFISY	TLR10	626	Q9BXR5
AFDRHFRTLKNLYGK	SYNJ1	281	O43426
QNNFDYKRFIKFARV	SAMHD1	326	Q9Y3Z3
QALARHFYIKEKDFN	SAMD9L	1086	Q8IVG5
RRKFKQIVTAVYFCH	SIK3	166	Q9Y2K2
HLRFQHYKAKRVFSA	SIAH3	16	Q8IW03
FKNIVYTYRIFREKH	SH2D1B	46	O14796
YTIFNHDFRRAFKKI	ADRA2A	441	P08913
FFNKKDILKLHSRFY	CIB2	21	O75838
NFYRAFNLDKDVFIH	C11orf40	56	Q8WZ69
KAHRAVLAAFSNYFK	ZBTB25	36	P24278
RGRFSFEVFRFVKHK	ZPLD1	271	Q8TCW7
GKFFRDSYKLIIHQR	ZNF749	646	O43361
RQRFIDFFKRNEHTY	AARS1	11	P49588
AERTYKQRFLFAKLF	PHTF1	551	Q9UMS5
DRLLYDIVFKHFKRN	SP100	46	P23497
HEKLKEAYALFQFFQ	SPTA1	1706	P02549
YYDHLRSAAKKRFFR	PHLDB1	1311	Q86UU1
FAEFYNRLKQIKEFH	SF3A3	81	Q12874
ERVKEHFYKQYVGRF	FARS2	91	O95363
VVALFVYRKNHRDFE	UNC5C	396	O95185
IFNHLHFRKKFNIYL	ATP6V0A2	571	Q9Y487
FRVFDVRHKSNKDYL	ZFHX3	231	Q15911
VIKQAAREKNFHIFY	MYO3B	521	Q8WXR4